Durvalumab Consolidation Extends Progression-Free Survival in Unselected Patients with Locally Advanced NSCLC

TON Web Exclusives - Lung Cancer

For years, the standard of care for patients with unresectable, locally advanced (stage III) non–small-cell lung cancer (NSCLC) and a good performance status has been platinum-based doublet chemotherapy combined with radiotherapy (chemoradiotherapy [CRT]). Clinical results associated with CRT, however, remain poor—at 5 years, only 15% of these patients are alive and 12% are free from disease progression.1

The ongoing phase 3 PACIFIC study is a randomized, double-blind, placebo-controlled, multicenter trial of durvalumab as consolidation therapy for patients with unresectable, locally advanced NSCLC who have not progressed following platinum-based CRT. The primary end points of the trial are progression-free survival (PFS) and overall survival (OS); secondary end points include landmark PFS and OS, objective response rate, and duration of response.2,3

Durvalumab (Imfinzi) is a selective, high-affinity, human IgG1 monoclonal antibody that blocks programmed death ligand 1 (PD-L1). On May 1, 2017, the FDA granted accelerated approval to durvalumab for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy, or who have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.2

Interim results of the PACIFIC trial were presented at the European Society for Medical Oncology Congress in Madrid, Spain, in September 2017. After randomization, 473 patients with stage III NSCLC received durvalumab consolidation and 236 patients received placebo. The median PFS from randomization was 16.8 months with durvalumab compared with 5.6 months with placebo (stratified hazard ratio for disease progression or death, 0.52; 95% confidence interval, 0.42-0.65; P <.001).3,4 The 1-year PFS rates were 55.9% for durvalumab consolidation and 35.3% for placebo; 18-month PFS rates were 44.2% and 27.0%, respectively.3,4 The PFS benefit was observed across all prespecified subgroups and irrespective of baseline expression of PD-L1 on tumor cells.3

The most frequent treatment-related adverse events (AEs) in the durvalumab and placebo groups, respectively, were cough (35.4% vs 25.2%), pneumonitis/radiation pneumonitis (33.9% vs 24.8%), fatigue (23.8% vs 20.5%), dyspnea (22.3% vs 23.9%), and diarrhea (18.3% vs 18.8%). Grade 3/4 AEs were observed in 29.9% of durvalumab-treated patients compared with 26.1% of patients receiving placebo; 15.4% of patients in the durvalumab group discontinued treatment because of AEs versus 9.8% of patients in the placebo group.3

“For patients with locally-advanced unresectable NSCLC who have completed chemoradiation therapy, Imfinzi represents a potential new treatment option in the context of clear unmet clinical need. Durvalumab overtly prolongs the period in which the disease is controlled with reasonable side effects. In addition, it offers hope to increase the cure rate in this setting, but more mature follow-up is needed to assess its impact on survival,” said Luis Paz-Ares, MD, Professor of Medicine at the Hospital Universitario Doce de Octubre, Madrid, Spain, and Principal Investigator of the PACIFIC trial, in a recent press release.3

On July 31, 2017, durvalumab received breakthrough therapy designation from the FDA as a potential treatment for patients with locally advanced, unresectable NSCLC whose disease has not progressed following platinum-based CRT. As of September 2017, the developer of durvalumab was discussing regulatory submission of data from the PACIFIC trial with global health authorities.3

References
1. Aupérin A, Le Péchoux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol. 2010;28:2181-2190.
2. US Food and Drug Administration. AstraZeneca’s Imfinzi (durvalumab) receives US FDA accelerated approval for previously treated patients with advanced bladder cancer. www.astrazeneca.com/media-centre/press-releases/2017/astrazenecas-imfinzi-durvalumab-receives-us-fda-accelerated-approval-for-previously-treated-patients-with-advanced-bladder-cancer-01052017.html. Accessed January 25, 2018.
3. AstraZeneca. AstraZeneca presents superior progression-free survival for Imfinzi in the PACIFIC trial of patients with locally-advanced unresectable lung cancer at ESMO 2017 Congress. www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-presents-superior-progression-free-survival-for-imfinzi-in-the-pacific-trial-of-patients-with-locally-advanced-unresectable-lung-cancer-at-esmo-2017-congress-08092017.html. Accessed January 25, 2018.
4. Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer. N Engl J Med. 2017;377:1919-1929.

Related Items
Osimertinib Nearly Doubles PFS, Receives Breakthrough Therapy Designation in Frontline Treatment of EGFR-Positive NSCLC
TON Web Exclusives published on February 12, 2018 in Lung Cancer
Pembrolizumab, Pemetrexed, and Platinum Chemotherapy Combination Shows Improved OS and PFS in Patients with Metastatic Nonsquamous Metastatic NSCLC
TON Web Exclusives published on February 12, 2018 in Lung Cancer
FDA Approves Alectinib for ALK-Positive, Metastatic Non–Small-Cell Lung Cancer
TON Web Exclusives published on February 12, 2018 in Lung Cancer
Therapeutic Options for Patients with ALK-Positive NSCLC After Disease Progression with Crizotinib
TON Web Exclusives published on February 12, 2018 in Lung Cancer
Next-Generation ALK/ROS1 Inhibitor Lorlatinib Shows Strong, Durable Responses in Advanced NSCLC
TON Web Exclusives published on February 12, 2018 in Lung Cancer
Final Results of ALTA Trial Verify Brigatinib Activity in ALK-Positive NSCLC
TON Web Exclusives published on January 29, 2018 in Lung Cancer
Afatinib Indication Expands to Include Metastatic NSCLC with Rare, Nonresistant EGFR Mutations
TON Web Exclusives published on January 29, 2018 in Lung Cancer
First-Line Treatment with Dabrafenib plus Trametinib Shows Substantial Clinical Activity in BRAF V600E–Mutated Metastatic NSCLC
TON Web Exclusives published on January 29, 2018 in Lung Cancer
Rovalpituzumab Tesirine (Rova-T), a First-in-Class Antibody-Drug Conjugate, Is Active in Patients with Recurrent Small-Cell Lung Cancer
TON Web Exclusives published on January 29, 2018 in Lung Cancer
Alectinib New Standard of Care for ALK-Positive Non–Small-Cell Lung Cancer
Phoebe Starr
TOP - November 2017, Vol 10, No 4 published on November 13, 2017 in Lung Cancer
Last modified: January 29, 2018

©2018 Green Hill Healthcare Communications, LLC, an affiliate of The Lynx Group. All rights reserved.
1249 South River Road - Suite 202, Cranbury, NJ 08512